Characterization of Sleep Habits and Medication Outcomes for Sleep Disturbance in Children and Adults With Angelman Syndrome

Abstract

Purpose: The purpose of this study was to characterize the sleep habits of 50 clinically referred individuals with Angelman syndrome (AS) and to retrospectively compare the effectiveness/tolerability of the three most commonly prescribed sleep medications in the sample. Methods: An experienced physician assigned a Clinical Global Impressions-Severity scale (CGI-S) score for each subject’s AS-specific symptoms. Caregivers completed the Child Sleep Habits Questionnaire (screen for sleep problems in school-aged (4-10 years) children), a screening assessment for sleep problems. Caregivers provided information about medication trials targeting disturbed sleep, with the physician assigning a CGI-Improvement scale (CGI-I) score for each trial. Results: Linear regression showed significant negative association between age and CSHQ score. In their lifetime, 72% of participants had taken a medication for sleep, most commonly melatonin, clonidine and trazodone. The majority continued these for six months or longer. With these medications, many demonstrated significant improvement in sleep disturbances, with no difference in odds of improvement between medications. Conclusion: Disturbed sleep was common in this cohort and significantly worse in younger-aged participants. The majority received at least one medication trial for disturbed sleep and each of the most commonly prescribed medication was effective for a substantial percentage of participants. Most participants remained on medication for at least six months, suggesting favorable tolerability. An experienced physician assigned a Clinical Global Impressions-Severity scale (CGI-S) score for each subject’s AS-specific symptoms. Caregivers completed the Child Sleep Habits Questionnaire (screen for sleep problems in school-aged (4-10 years) children), a screening assessment for sleep problems. Caregivers provided information about medication trials targeting disturbed sleep, with the physician assigning a CGI-Improvement scale (CGI-I) score for each trial. Linear regression showed significant negative association between age and CSHQ score. In their lifetime, 72% of participants had taken a medication for sleep, most commonly melatonin, clonidine and trazodone. The majority continued these for six months or longer. With these medications, many demonstrated significant improvement in sleep disturbances, with no difference in odds of improvement between medications. Disturbed sleep was common in this cohort and significantly worse in younger-aged participants. The majority received at least one medication trial for disturbed sleep and each of the most commonly prescribed medication was effective for a substantial percentage of participants. Most participants remained on medication for at least six months, suggesting favorable tolerability.